Literature DB >> 7868918

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography.

J L Casey1, P A Keep, K A Chester, L Robson, R E Hawkins, R H Begent.   

Abstract

A new procedure is described for the purification of an anti-carcinoembryonic antigen (CEA) single chain Fv (scFv), referred to as MFE-23, from bacterial supernatant. A simple insertion of a hexa-histidine tail fused at the C-terminus (MFE-23 His) provides an affinity tag which selectively binds to transition metal ions immobilised on an iminodiacetic acid (IDA) derivitised solid phase matrix. This method proved to be superior to standard CEA antigen affinity chromatography in the following ways. (1) A higher yield was produced (10 mg/l as opposed to 2.2 mg/l of bacterial supernatant). The latter figure was largely affected by the limited availability (size of the column) of immobilised CEA antigen. (2) Scale-up was relatively simple and less costly. (3) The risk of tumour derived antigen leaching from the column is eliminated. Results showed that immobilised Cu2+ ions were more effective than Ni2+ and Zn2+ ions in retaining the His tagged product giving a 90% pure product on elution. Clinical grade material was generated using size exclusion chromatography to remove aggregated material, and Detoxi gel to remove bacterial endotoxins. Validation assays to measure DNA, copper and endotoxins were performed to assess the levels of contaminants. MFE-23 His retained 84% antigen binding after 6 months storage at 4 degrees C and > 75% after radiolabelling. Further experiments confirmed that the His tail did not affect biodistribution and tumour localisation in nude mice bearing human colorectal tumour xenografts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868918     DOI: 10.1016/0022-1759(94)00278-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

1.  Construction and expression of single-chain Fv antibody against human bladder carcinoma.

Authors:  L Z Yu; S Xiao; H L Huang; Z Gu; F L Gu; Y L Guo
Journal:  Urol Res       Date:  1996

2.  Human scFv antibody fragments specific for hepatocellular carcinoma selected from a phage display library.

Authors:  Bing Yu; Ming Ni; Wen-Han Li; Ping Lei; Wei Xing; Dai-Wen Xiao; Yu Huang; Zhen-Jie Tang; Hui-Fen Zhu; Guan-Xin Shen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Construction, expression and in vitro biological behaviors of Ig scFv fragment in patients with chronic B cell leukemia.

Authors:  Lijuan Zhu; Wenjun Liao; Huifen Zhu; Ping Lei; Zhihua Wang; Jingfang Shao; Yue Zhang; Guanxin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

4.  Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.

Authors:  Claire L Dobson; Sarah Main; Philip Newton; Matthieu Chodorge; Karen Cadwallader; Robin Humphreys; Vivian Albert; Tristan J Vaughan; Ralph R Minter; Bryan M Edwards
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

5.  Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).

Authors:  R J Francis; S J Mather; K Chester; S K Sharma; J Bhatia; R B Pedley; R Waibel; A J Green; R H J Begent
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

6.  Stepwise molecular display utilizing icosahedral and helical complexes of phage coat and decoration proteins in the development of robust nanoscale display vehicles.

Authors:  Kristin N Parent; Christina T Deedas; Edward H Egelman; Sherwood R Casjens; Timothy S Baker; Carolyn M Teschke
Journal:  Biomaterials       Date:  2012-05-08       Impact factor: 12.479

7.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Authors:  J L Casey; D J King; L C Chaplin; A M Haines; R B Pedley; A Mountain; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.

Authors:  Vivi Joosten; Christien Lokman; Cees AMJJ Van Den Hondel; Peter J Punt
Journal:  Microb Cell Fact       Date:  2003-01-30       Impact factor: 5.328

9.  Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.

Authors:  M Coelho; P Gauthier; M Pugnière; F Roquet; A Pèlegrin; I Navarro-Teulon
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

10.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  A Mayer; S K Sharma; B Tolner; N P Minton; D Purdy; P Amlot; G Tharakan; R H J Begent; K A Chester
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.